Sunitinib Multi-Targeted Oral Anti-Angiogenic Therapy Responses in Lung Cancer
REFERENCE: Abstract 7001
Mark A. Socinski, Univerisity of North Carolina, Chapel Hill
The use of anti-angiogenic therapy for treating patients with non-small cell lung cancer received a boost at the 2006 ASCO Annual Meeting in Atlanta by results from a study looking at the use of sunitinib, a multi-targeted oral drug that achieved partial responses and stable disease among pretreated patients with non-small cell lung cancer. Mark Socinski from the University of North Carolina at Chapel Hill said the results suggest that sunitinib may be even more useful when used in earlier stages of treatment.
Sunitinib in Lung Cancer: Results Assessed
Bruce Johnson, Dana-Farber Cancer Institute, Boston
During the ASCO meeting, Bruce Johnson commented on the findings presented by Mark Socinski. Peter Goodwin asked him to assess the possible value of sunitinib and the scope of such targeted agents for treating patients with non-small cell lung cancer.
Dasatinib: Possible Option for treating Patients in Chronic Phase Chronic Myeloid Leukemia Resistant to Imatinib
REFERENCE: Abstract 6507
Neil Shah, University of California, San Francisco
One of the options for treating patients with chronic phase chronic myeloid leukemia resistant to imatinib might be the new targeted therapy dasatinib. ASCO delegates heard more from Neil Shah, of the University of California in San Francisco.
Vaccine Promise for Chronic Myeloid Leukemia
REFERENCE: Abstract 6509
Doug Smith, Johns Hopkins Cancer Center, Baltimore
A vaccine for chronic myeloid leukemia has produced molecular remissions in a small number of patients. Results were presented at the 2006 ASCO meeting by Doug Smith of Johns Hopkins Cancer Center in Baltimore, who described to Derek Thorne how the vaccine has been performing, and why chronic myeloid leukemia might be a good disease in which to use this approach.